SANTA CRUZ BIOTECHNOLOGY, INC.

Myeloid Marker (BM-3): sc-65222

BACKGROUND

Myeloid cells originate in the bone marrow during hematopoiesis and encompass all hemopoietic cells except the lymphoid cells (T cells, B cells, NK cells and dendritic cells). Vascular endothelial cells can differentiate from common myeloid progenitors, and these cells that form the bone marrow-derived myeloid lineage express markers such as CD31, von Willebrand factor and Tie2. Other myeloid markers may be used to track certain diseases, such as Kawasaki disease, a self-limited vasculitis that affects many organs, including the skin and mucous membranes, lymph nodes, blood vessel walls and heart.

REFERENCES

1. Bettelheim, P., Paietta, E., Majdic, O., Gadner, H., Schwarzmeier, J. and Knapp, W. 1982. Expression of a myeloid marker on TdT^+ acute lymphocytic leukemic cells: evidence by double-fluorescence staining. Blood 60: 1392-1396.
2. Dolinsky, Z.S., Morse, D.E., Kaplan, R.F., Meyer, R.E., Corry, D. and Pomerleau, O.F. 1987. Neuroendocrine, psychophysiological and subjective reactivity to an alcohol placebo in male alcoholic patients. Alcohol. Clin. Exp. Res. 11: 296-300.
3. Gabius, S., Joshi, S.S., Gabius, H.J. and Sharp, J.G. 1991. Establishment, characterization and determination of cell surface sugar receptor (lectin) expression by neoglycoenzymes of a human myeloid marker-expressing B lymphoblastoid cell line. Anticancer Res. 11: 793-800.
4. Welker, P., Grabbe, J., Zuberbier, T., Guhl, S. and Henz, B.M. 2000. Mast cell and myeloid marker expression during early *in vitro* mast cell differentiation from human peripheral blood mononuclear cells. J. Invest. Dermatol. 114: 44-50.
5. Fujiyama, S., Amano, K., Uehira, K., Yoshida, M., Nishiwaki, Y., Nozawa, Y., Jin, D., Takai, S., Miyazaki, M., Egashira, K., Imada, T., Iwasaka, T. and Matsubara, H. 2003. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ. Res. 93: 980-989.
6. Lin, Y., Roberts, T.J., Sriram, V., Cho, S. and Brutkiewicz, R.R. 2003. Myeloid marker expression on antiviral $CD8^+$ T cells following an acute virus infection. Eur. J. Immunol. 33: 2736-2743.
7. Viemann, D., Strey, A., Janning, A., Jurk, K., Klimmek, K., Vogl, T., Hirono, K., Ichida, F., Foell, D., Kehrel, B., Gerke, V., Sorg, C. and Roth, J. 2005. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 105: 2955-2962.
8. Bailey, A.S., Willenbring, H., Jiang, S., Anderson, D.A., Schroeder, D.A., Wong, M.H., Grompe, M. and Fleming, W.H. 2006. Myeloid lineage progenitors give rise to vascular endothelium. Proc. Natl. Acad. Sci. USA 103: 13156-13161.
9. Frey, A.B. 2006. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116: 2587-2590.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

Myeloid Marker (BM-3) is a mouse monoclonal antibody raised against nuclei from Pokeweed mitogen stimulated with peripheral blood lymphocytes of human origin.

PRODUCT

Each vial contains 100 µg IgG_1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Myeloid Marker (BM-3) is recommended for detection of Myeloid Marker of human origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10^6 cells).

Suitable for use as control antibody for Myeloid Marker siRNA (h): sc-72128.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.